This company has been marked as potentially delisted and may not be actively trading. CinCor Pharma (CINC) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock CINC Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Novel Antihypertensive Reduced Blood Pressure in Primary AldosteronismJuly 28, 2025 | msn.comAstraZeneca’s Phase III trial of baxdrostat shows mean SBP reductionJuly 16, 2025 | msn.comAstra Says Potential Blockbuster Reduced High Blood PressureJuly 14, 2025 | msn.comAstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To ReactJuly 14, 2025 | msn.comAstraZeneca drug lowers high blood pressure in late-stage studyJuly 14, 2025 | msn.comFormer CinCor execs raise $3.8M for new Cincinnati biopharma firmJanuary 28, 2025 | bizjournals.comCinRx Pharma portfolio company CinDome raises $40M toward Series B roundMay 28, 2024 | bizjournals.comDelveInsight Business Research, LLP: Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | finanznachrichten.deGlobal Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | tmcnet.comCinCor Pharma Inc.March 22, 2024 | thestreet.comPurdue Pharma to plead guilty in $8bn opioid settlementDecember 12, 2023 | bbc.comBImpel Pharmaceuticals hit by another C-suite departureDecember 6, 2023 | bizjournals.comCatalyst Pharma's Finance Chief to Retire, Be Succeeded by Impel's CFODecember 4, 2023 | marketwatch.comSmall Pharma Inc. (DMT.V)November 4, 2023 | ca.finance.yahoo.comAbivax Readies $250 Million U.S. IPO For Drug PipelineOctober 20, 2023 | msn.comDiabetic Kidney Disease Global Market Report 2023June 9, 2023 | uk.finance.yahoo.com8-K: IMPEL PHARMACEUTICALS INCMay 11, 2023 | marketwatch.comChronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsightMay 9, 2023 | finance.yahoo.comFinancial Results for the Year Ended 31 December -3-April 25, 2023 | finanznachrichten.deCinCor Pharma, Inc. (NASDAQ:CINC) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarch 20, 2023 | marketbeat.comNASDAQ Biotechnology IndexMarch 16, 2023 | reuters.comHOOKIPA Pharma Appoints Terry Coelho to its Board of DirectorsMarch 13, 2023 | finance.yahoo.comBoothbay Fund Management LLC Purchases Shares of 13,718 CinCor Pharma, Inc. (NASDAQ:CINC)March 2, 2023 | marketbeat.comCinCor Pharma (Nasdaq:CINC) HeadlineTrading was temporarily halted for "CINC" at 07:02 PM with a stated reason of "News pending."...February 24, 2023 | marketbeat.comCinCor Pharma, Inc. (NASDAQ:CINC) Given Average Recommendation of "Moderate Buy" by AnalystsFebruary 23, 2023 | marketbeat.comCinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of BaxdrostatFebruary 21, 2023 | finance.yahoo.comState Board of Administration of Florida Retirement System Invests $230,000 in CinCor Pharma, Inc. (NASDAQ:CINC)February 15, 2023 | marketbeat.comThere's a Lot to Love About Mineralys' Valentine's Day IPO (CINC)MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million...February 13, 2023 | marketbeat.comCinCor Pharma, Inc. (NASDAQ:CINC) Short Interest Down 74.7% in JanuaryFebruary 10, 2023 | marketbeat.comAs demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023February 9, 2023 | msn.comThese 2 Healthcare Stocks Have Doubled in 2023 (CINC)Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.February 1, 2023 | marketbeat.comCinCor Pharma, Inc. (NASDAQ:CINC) Receives Consensus Rating of "Moderate Buy" from BrokeragesJanuary 29, 2023 | marketbeat.comCinCor Pharma, Inc. (NASDAQ:CINC) Short Interest Down 38.2% in JanuaryJanuary 27, 2023 | marketbeat.comADRs End Higher; AstraZeneca, Barclays Trade ActivelyJanuary 23, 2023 | marketwatch.comBritain's AstraZeneca launches tender offer for CinCor PharmaJanuary 23, 2023 | msn.comAstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.January 23, 2023 | finance.yahoo.comCambridge Investment Research Advisors Inc. Invests $204,000 in CinCor Pharma, Inc. (NASDAQ:CINC)January 16, 2023 | marketbeat.comWill 2023 be the year that pharma M&A makes a comeback?January 12, 2023 | msn.comCinCor Pharma (NASDAQ:CINC) Lowered to Equal Weight at BarclaysJanuary 12, 2023 | marketbeat.comAstraZeneca Is Acquiring CinCor Pharma: Market Values Interesting CVR At $3.21January 12, 2023 | seekingalpha.comAstraZeneca reaches deal to buy CinCor Pharma for up to $1.8 billionJanuary 11, 2023 | bizjournals.comAstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor BuyoutJanuary 10, 2023 | finance.yahoo.comEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of CinCor Pharma, Inc - CINCJanuary 10, 2023 | marketwatch.comAstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor BuyoutJanuary 10, 2023 | finance.yahoo.comCinCor Pharma Target of Unusually High Options Trading (NASDAQ:CINC)January 10, 2023 | marketbeat.comAstraZeneca buying hypertension-focused CinCor for up to $1.8 billionJanuary 9, 2023 | msn.comAstraZeneca to Buy CinCor Pharma for Up to $1.8 BillionJanuary 9, 2023 | finance.yahoo.comAstraZeneca reaches deal to buy CinCor Pharma for up to $1.8BJanuary 9, 2023 | finance.yahoo.comAstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion DealJanuary 9, 2023 | finance.yahoo.comBiotechs CinCor, Albireo Jump on Takeovers by Larger DrugmakersJanuary 9, 2023 | finance.yahoo.com Get CinCor Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CINC and its competitors with MarketBeat's FREE daily newsletter. Email Address CINC Media Mentions By Week CINC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CINC News Sentiment▼0.300.61▲Average Medical News Sentiment CINC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CINC Articles This Week▼00▲CINC Articles Average Week Get CinCor Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CINC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MOR News Today CALT News Today ZYME News Today MBX News Today AVTE News Today CYBN News Today VIRI News Today PYRGF News Today ELYM News Today OSTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CINC) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CinCor Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CinCor Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access